Model II adjusted for: sex, age, obesity, diabetes, chronic renal insufficiency, heart failure, asthma, immunosuppression, Platelets, C-reactive protein, procalcitonin, alanine aminotransferase, aspartate aminotransferase, lung damage on computed tomography, sequential organ failure assessment, tocilizumab, renal replacement therapy, sepsis, septic shock, acute kidney failure, pneumonia associated with IMV, plateau pressure 24 h after IMV, driving pressure 24 h after IMV. This evidence concerns the gene CRP and susceptibility to pneumonia measurement.